­CAPhO Conference 2026

Session Detail

Saturday
Apr 25 2026
–
Salon CD
Plenary session
AI Utilization in Healthcare: A Cancer Pharmacy Perspective
Presenters
Bastiaan Buijtenhuijs
Photo of Bastiaan Buijtenhuijs
Photo of Bastiaan Buijtenhuijs
Bastiaan Buijtenhuijs
Head of Product and Lead Oncology Pharmacist, iQ HealthTech, Co-chair BOPA AI Cancer advisory group, BOPA

Bastiaan Buijtenhuijs is Head of Product and Lead Oncology Pharmacist at iQ HealthTech, where he oversees the development of iQemo, a leading systemic anti-cancer therapy (SACT) prescribing system used across the UK and internationally. In this role, he bridges clinical oncology pharmacy needs with digital innovation, ensuring that user requirements are effectively translated into product functionality.
 
Bastiaan completed his MSc through the NHS Digital Academy (Cohort 3), focusing his dissertation on implementing AI-driven clinical decision-support systems in oncology pharmacy. He has also undertaken the NHS Digital Academy leadership programme, equipping him with strategic insight into digital transformation in healthcare. Bastian is working towards his PhD in Applied Artificial Intelligence at University College London.
 
His research interests include the application of AI in oncology pharmacy, clinical decision support and digital health innovation. He co-chairs the British Oncology Pharmacy Association (BOPA) Artificial Intelligence Cancer Advisory Group and regularly contributes to webinars and educational events on AI in pharmacy practice.
 
Bastiaan is an active presenter and advocate for digital health, with recent talks including BOPA’s 2025 webinar on administrative efficiency in oncology pharmacy and AI use cases in cancer pharmacy at UK SACT Board. 

Bastiaan Buijtenhuijs
Co-chair BOPA AI Cancer advisory group, BOPA

Artificial intelligence (AI) is already reshaping cancer services—improving diagnostics, streamlining oncology pharmacy workflows, and enabling safer, more personalised systemic anti-cancer therapy (SACT). This session reviews practical AI use cases relevant to cancer pharmacists, including workflow optimisation, aseptic preparation technologies, AI-assisted prescription verification and risk stratification, and toxicity prediction. Using NHS and international examples plus the BOPA AI Specialist Advisory Group priorities, we’ll explore benefits, limitations, governance, and how pharmacists can lead safe, ethical adoption in real-world practice.

Objectives:

  1. AI types and use-case mapping
    • By the end of the session, participants will be able to identify at least 4 AI types (e.g., rule-based, machine learning, deep learning, generative AI) and complete a mapping exercise that links at least 6 oncology-pharmacy use-case domains to one potential application in their own service, recorded on the session worksheet.
  2. Governance and ethics
    • By the end of the session, participants will be able to list at least 4 governance/ethical requirements for implementing AI in oncology pharmacy and will write 2 feasible mitigation actions (aligned to their workplace) to address identified risks, documented on the session worksheet.
  3. Engaging with BOPA AI CAG and Professional Networks to Influence AI Adoption
    • By the end of the session, participants will be able to describe 3 ways the BOPA AI CAG (and at least one other relevant group/network) can influence safe and effective AI adoption in oncology pharmacy, and will identify 1 specific opportunity to get involved (e.g., join a working group, contribute to consultation, participate in a survey/pilot) by writing a personal commitment action they will complete within 4 weeks of the session.